Regulation of Cellular Metabolism and Cytokines by the Medicinal Herb Feverfew in the Human Monocytic THP-1 Cells by Chen, Chin-Fu & Cheng, Chun-Huai
Advance Access Publication 11 June 2007 eCAM 2009;6(1)91–98
doi:10.1093/ecam/nem061
Original Article
Regulation of Cellular Metabolism and Cytokines by the Medicinal
Herb Feverfew in the Human Monocytic THP-1 Cells
Chin-Fu Chen and Chun-Huai Cheng
Department of Genetics and Biochemistry, Clemson University, Clemson, SC, USA
The herb feverfew is a folk remedy for various symptoms including inflammation.
Inflammation has recently been implicated in the genesis of many diseases including cancers,
atherosclerosis and rheumatoid arthritis. The mechanisms of action of feverfew in the human
body are largely unknown. To determine the cellular targets of feverfew extracts, we have
utilized oligo microarrays to study the gene expression profiles elicited by feverfew extracts in
human monocytic THP-1 cells. We have identified 400 genes that are consistently regulated by
feverfew extracts. Most of the genes are involved in cellular metabolism. However, the genes
undergoing the highest degree of change by feverfew treatment are involved in other pathways
including chemokine function, water homeostasis and heme-mediated signaling. Our results also
suggest that feverfew extracts effectively reduce Lipopolysaccharides (LPS)-mediated TNF-a
and CCL2 (MCP-1) releases by THP-1 cells. We hypothesize that feverfew components mediate
metabolism, cell migration and cytokine production in human monocytes/macrophages.
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Introduction
Feverfew (Tanacetum parthenium), a member of the
family Compositae, is an aromatic perennial herb with
yellowish-green chrysanthemum-like leaves and small
daisy-like flowers. Feverfew has traditionally been used,
through consumption of leaves or the aerial parts, for
numerous symptoms including inflammation, fever,
rheumatism, asthma and stomachache (1). During the
last few decades, feverfew has also been used for migraine
prophylaxis although results from early clinical trials
were mixed due to inadequate trial design and low
power (2). A recent study with randomized, double-blind,
placebo-controlled, multi-center, parallel-group design,
using feverfew extracts in capsules, has suggested that
feverfew may indeed reduce the frequency of migraine
attack (3).
Although several mechanisms have been proposed to
explain the therapeutic effect of feverfew in migraine (4),
the mechanism of action of feverfew remains largely
unknown. Due to the complex chemical composition
of feverfew extracts and its historically multi-purpose
usage, it is reasonable to expect that the mechanisms
and pathways by which it functions in human cells
are complex. Sesquiterpene lactone parthenolide long
believed to be one of the main active components of
feverfew extracts, has multiple physiologic effects, includ-
ing anti-tumor activity, inhibition of DNA synthesis,
inhibition of cell proliferation in different cancer cell
lines (5,6), mediation of inflammation via cytokines
(Tumor Necrosis Factor -alpha (TNF-a), Interleukin-1b
(IL-b) and Interleukin-6 (IL-6)) (7), chemokines (IL-b)
(8), lipids (prostaglandins) (9,10), COX-2 (7,11) and
leukotrienes (11).
In spite of these reports, the mechanisms by which
parthenolide acts on cells remain unclear. Although an
early study in rats suggested that TNF-a production
in alveolar macrophages was substantially inhibited
by parthenolide (7), a recent study in mice, reported
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properly cited.that expression of IL-6 was moderately suppressed
by parthenolide but that expression of TNF-a, IL-1b
and COX-2 was not affected (12). Further, while clinical
trials using whole extracts have produced promising
results, a clinical trial with primary focus on parthenolide
enrichment for prevention of migraine failed to demon-
strate a significant beneficial effect (13). It is therefore,
unclear whether parthenolide is indeed the primary active
ingredient of feverfew extracts.
Biological systems function in general by interactions
at multiple levels and among many cellular components.
Microarray technology allows simultaneous measurement
of the gene expression of the entire genome and can
provide a global view of gene networking and biological
processes. Most importantly, microarray analysis does
not require a priori assumptions or knowledge of the
biological system and can lead to new hypotheses based
on the patterns of gene expression. Microarray analysis
has been successfully applied to research on various
diseases and systems including prostate cancer (14,15),
breast cancer (16), leukemia and lymphoma (17), lung
diseases (18), cardiovascular diseases (19,20), infectious
diseases (21), toxicology (22), nutrition (23) and the effect
of herbs (24). DNA microarrays are extremely useful in
elucidation of molecular mechanism of action of an herb
(25) because herbal medicine by its complex nature
contains a broad spectrum of chemicals that may
simultaneously affect multiple cellular targets. In this
study, we utilized oligonucleotide microarray techno-
logy to study pathways in the response of the human
monocytic cell line THP-1 to feverfew extracts. Since
monocytes/macrophages are key mediators of inflamma-
tion and widely distributed in the body (26–28), mono-
cytic cell lines present an appropriate model system to
study immune responses to feverfew extracts.
Methods
Cell Culture and Feverfew Extracts
The human monocytic cell line THP-1 (ATCC 202-TIB)
(29) was obtained from ATCC (American Type Culture
Collection, Manassas, VA, USA) and cultured according
to their recommendations. The cells express various
receptors that are found in normal monocytes and
have been a model system for macrophage biology and
leukemia since 1980. The feverfew extracts were gifts
from Phyto-Technologies (Woodbine, IA, USA).
They were prepared by sonicating dry feverfew powder
in 90% ethanol (30min at room temperature) followed
by carbon dioxide supercritical fluid extraction (SFE,
400bar, 60 C). The final stock concentration was 20%
dry weight (w/v) in dichloromethane (as solvent) and
typically contained 0.981mg/ml of parthenolide (the
presumptive active ingredient), estimated by HPLC
fingerprinting. Of note, literature search did not reveal
any evidence that exposure to dichloromethane changes
structural components of feverfew extracts.
Endotoxin And Cytotoxicity Assays
Endotoxins are strong immunological stimuli and are
part of the outer cell wall of Gram-negative bacteria.
Since, herbs under natural growing conditions are
associated with bacteria, we assayed the levels of
endotoxin in the herb extracts. The levels of endotoxin
of three different extracts of feverfew were less than the
lowest detectable level, (0.005EU/ml) using the kinetic
chromogenic LAL method (Cambrex, Walersville, MD,
USA), the most sensitive (down to 0.005EU/ml) method
available. Cytotoxicity studies indicated that when THP-1
cells were treated for 3h at doses equivalent to 0.01%,
0.02%, or 0.04% dry weight feverfew, cell viability did
not vary from the control (data not shown). The viability
of THP-1 cells exposed to feverfew extracts decreased
starting at doses equivalent to 0.04% dry weight after
24h incubation. Viability further decreased to  20%
of controls at 0.1% dry weight after 24h incubations
(data not shown). On the basis of these analyses,
exposure to the equivalent of 0.01% dry weight feverfew
for 3h was used for experiments unless otherwise noted.
Human Gene Expression Microarrays
THP-1 cells were treated with dichloromethane (solvent
control) or feverfew extracts (SFE) equivalent to 0.01%
(w/v, dry weight) for 3h. Four independent experiments
were performed for each treatment. To maximize the
contrast between samples, we implemented a loop
experimental design (30) with dye swap. Total RNA
was isolated using the Agilent Total RNA Isolation
Mini Kit (Agilent Technologies, Wilmington, DE, USA).
RNA samples were labeled with Cy3 or Cy5 fluorescent
dye and hybridized for 17h with Agilent Whole Human
Genome Oligo Microarray containing over forty
thousand human genes and transcripts (31). Microarray
slides were washed and scanned by Agilent G2505B
microarray scanner. Image processing and fluorescence
intensity were interpreted and analyzed by Agilent
Feature Extraction (version 8.5).
Data Processing and Statistical Analysis
Data normalization was performed by a non-linear
LOWESS method that utilizes gene intensity and spatial
information (32–34). Gene expression fold changes were
calculated as ratio of treatment (i.e. feverfew) divided by
control (solvent only). For statistical analysis, the fold
change ratios were transformed into logarithmic scale.
To select the genes that were differentially expressed,
we utilized the concept of false discovery rate (FDR)
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performed for four independent experiments using the
software program, Significance Analysis of Microarray
(SAM) (38). Experimental data were also analyzed using
the statistical package SYSTAT11 (SYSTAT Inc.,
Richmond, CA, USA). After statistical analysis, the
results were converted back to fold change for easy
comparison.
Gene Annotation by Gene Ontology (GO)
The Gene Ontology database (39,40) is a large
collaborative public database of controlled biological
vocabularies (i.e. ontologies) that describe gene products
based on their functionalities in the cell. In general, over-
or under-representation of GO terms were evaluated
using the Fisher Exact Probability Test. We utilized the
on-line program FatiGO (41) to produce (1) percentage
and number of genes appearing in a GO category;
(2) P-values from the Fisher exact test for each GO
term associated with the gene.
RT–PCR Primers
Both the oligos and the online tool for design of primer
sequences were from Integrated DNA Technologies
(Coralville, IA, USA). Our results suggested that
mRNAs for the GAPDH gene were not affected by
feverfew treatments (data not shown). The GAPDH gene
was therefore used as the reference gene. Genes of
interest and reference genes (i.e. GAPDH) were PCR-
amplified for construction of standard curves.
RNA Isolation for RT–PCR
Total RNA for both treatment and control groups was
isolated using the Absolutely RNA RT–PCR Miniprep
Kit (Stratagene, La Jolla, CA). Four independent
samples (different from that of the microarrays) were
obtained. Brilliant SYBR Green QRT-PCR Master Mix
Kit (1-Step) from Stratagene was used to prepare the
reaction mix. Reactions were carried out on an Mx3000
RT–PCR machine from Stratagene and programmed
using the following parameters: reverse transcription at
50 C for 30min, initial denaturation at 95 C for 10min,
followed by 40 cycles at 95 C for 30s, 50–60 C for 1min
and 72 C for 30s. Each PCR experiment per sample was
performed in triplicate on the real-time PCR instrument.
Changes in expression of genes were calculated by the
standard curve method and normalized to the reference
gene GAPDH.
ELISA Assays for Cytokines
Commercial enzyme-linked immunosorbent assay
(ELISA) kits (R&D Systems, Minneapolis, MN, USA)
were used to quantify TNF-a and CCL2. The absorbance
at 450nm was read by a microplate reader (model 680;
Bio-Rad Laboratories, Mississauga, ON, Canada) with
the wavelength correction set at 550nm. To calculate the
concentration of TNF-a and CCL2, a standard curve was
constructed using serial dilutions of cytokine standards
provided with the kit.
Results
Gene Expression Profiling of THP-1 Treated By Feverfew
Extracts
We have conducted microarray analyses to identify the
pathways involved in the response of human macro-
phages to feverfew extract (Supplementary Fig. 1).
Statistical analysis by the SAM software (38) suggested
that there were about 400 genes significantly altered in
cells treated with feverfew extracts (Supplementary Fig.
1). There were 245 up-regulated genes (increases ranging
from 17 to 1.21-fold over control) and 155 down-
regulated genes (decreases ranging from 0.8 to 0.3-fold
compared with controls).
Biological Pathways Affected By Feverfew Extracts
To gain insights into the mechanisms of human mono-
cytic responses to feverfew, we utilized Gene Ontology
(GO) annotation (Methods) to search for over-
representation of specific biological processes in the list
of differentially expressed genes. The percentage for each
category was calculated by the number of genes found
in that GO category divided by the number of total
genes available for annotation. Pathways prominent in
this analysis are ‘nucleobase, nucleoside, nucleotide and
nucleic acid metabolism’ (41%), ‘regulation of cellular
metabolism’ (35%), ‘alcohol metabolism’ (7.6%), ‘lipid
metabolism’ (7%) and ‘response to unfolded protein
(4%) (Supplementary Table 1).
Genes Highly Impacted By Feverfew Extracts
It would be expected that the THP-1 genes that are
highly responsive to feverfew represent the primary
targets of feverfew action. We have constructed a list
containing the 50 genes most highly affected by feverfew
(25 induced and 25 suppressed) (Table 1). Among the
most up-regulated genes are the genes coding for heme
oxygenase HMOX-1 (induced 417-fold, compared with
control); the heat shock protein, HSPA1A (10-fold
increase) and the chemokine IL-8 (9-fold increase).
The most highly suppressed genes include the genes
coding for SEMA4C (0.3-fold of control, function
unknown); RGS16 (regulator of G-protein signaling);
the orphan chemokine receptor CMKOR1 (also called
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Gene name Description Fold change Gene name Description Fold change
HMOX1 Heme oxygenase (decycling) 1 17.7 PSCD4 Pleckstrin homology, Sec7 and
coiled-coil domains 4
0.5
HSPA1A Heat shock 70kDa protein 1A 9.8 DKFZP434H132 DKFZP434H132 protein, mRNA 0.5
IL8 Interleukin 8 9.0 AQP1 Aquaporin 1 (channel-forming
integral protein, 28kDa)
0.5
DNAJB4 DnaJ (Hsp40) homolog,
subfamily B, member 4
6.5 ID3 Inhibitor of DNA binding 3,
dominant negative
helix-loop-helix protein
0.5
DNAJB1 DnaJ (Hsp40) homolog,
subfamily B, member 1
5.2 GADD45B Growth arrest and DNA-damage-
inducible, beta
0.5
SRXN1 Sulfiredoxin 1 homolog
(S. cerevisiae) (SRXN1)
4.6 CXXC5 CXXC finger 5 0.5
LOC344887 mRNA; cDNA DKFZp686B
14224 (from clone
DKFZp686B14224)
4.5 TFRC Transferrin receptor (p90, CD71) 0.5
EGR2 Early growth response 2
(Krox-20 homolog,
Drosophila)
4.2 THC2320257 Unknown 0.5
ADM Adrenomedullin 4.0 ENC1 Ectodermal-neural cortex
(with BTB-like domain)
0.5
BCL6 B-cell CLL/lymphoma 6
(zinc finger protein 51)
3.9 LOC389119 Similar to RIKEN cDNA
6530418L21
0.5
SLC7A11 Solute carrier family 7,
(cationic amino acid
transporter, yþ system)
member 11
3.8 ENST00000332281 Similar to snail homolog
3 (Drosophila)
0.5
THC2303268 HUMCATF catalase,
partial (39%)
3.6 ENST00000354543 mRNA; cDNA DKFZp586C0721
(from clone DKFZp586C0721)
0.5
GCLM Glutamate-cysteine ligase,
modifier subunit
3.5 GIMAP1 GTPase, IMAP family member 1 0.5
ATF3 Activating transcription factor 3 3.3 BC080552 cDNA clone IMAGE: 6254031 0.5
THC2310563 Unknown 3.2 CR593492 Full-length cDNA clone
CS0DI054YC18 of Placenta Cot
25-normalized of (human)
0.5
HSPH1 Heat shock 105kDa/110kDa
protein 1
3.1 HOXA9 Homeo box A9 0.5
HSPA6 Heat shock 70kDa protein 6
(HSP70B0)
2.9 BCOR BCL6 co-repressor 0.5
DUSP1 Dual specificity phosphatase 1 2.9 LFNG Lunatic fringe homolog
(Drosophila)
0.5
CR598364 Full-length cDNA clone
CS0CAP007YJ17 of Thymus
of (human)
2.9 PCANAP6 Prostate cancer associated
protein 6
0.5
FBXO30 F-box protein 30 2.8 ID2 Inhibitor of DNA binding 2,
dominant negative
helix-loop-helix protein
0.4
CXCL1 Chemokine (C-X-C motif)
ligand 1 (melanoma growth
stimulating activity, alpha)
2.7 FLJ45187 FLJ45187 protein 0.4
CR618687 Full-length cDNA clone
CS0CAP008YE23 of Thymus
of (human)
2.6 CCL2 Chemokine (C-C motif) ligand 2 0.4
PMAIP1 Phorbol-12-myristate-13-acetate-
induced protein 1
2.6 CMKOR1 Chemokine orphan receptor 1 0.4
BAG3 BCL2-associated athanogene 3 2.6 RGS16 Regulator of G-protein
signalling 16 sema domain,
immunoglobulin domain (Ig),
0.4
ARRDC4 Arrestin domain containing 4 2.5 SEMA4C Transmembrane domain (TM)
and short cytoplasmic domain,
(semaphorin) 4C
0.3
Fold changes in gene expression were calculated as values after feverfew treatment divided by control (solvent only) values.
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Interestingly, the expression of the gene AQP1 (water
channel-forming protein) was also significantly inhibited.
Verification by RT–PCR of Important Genes Responding
to Feverfew Extracts
Since each methodology has its own intrinsic limitations
and biases, it was important to verify the feverfew-
responsive genes identified through microarray analysis
using a different technology and independent samples.
We therefore, performed RT-PCR, isolating RNAs
for 10 representative feverfew-responsive THP-1 genes.
Four independent experiments were performed using cells
exposed to feverfew under the same conditions as in the
microarray experiments. The results from real-time PCR
were similar in trend to the microarray experiments,
(Table 2). For example, AQP1 expression was reduced
0.5-fold on average by feverfew extracts in microarray
experiments and was similarly reduced 0.4-fold in
RT-PCR experiments. The consistency of the microarray
and RT-PCR results reinforces the validity and power
of our microarray analyses.
Inhibition of Cytokine TNF-a and CCL2 Production
by Feverfew Extracts
To elucidate the functional roles of feverfew, we tested
whether feverfew extracts can interfere with cytokine
production in THP-1 cells. Although TNF-a, a key
cytokine involved in inflammation, does not appear in
the list of feverfew-responsive genes in microarray
analysis, treatment with parthenolide has been reported
to inhibit LPS mediated TNF-a production in rodent
models (7,42). In activated macrophages, a major source
of TNF, high levels of TNF-a are produced in response
to bacteria or parasitic proteins (as well as to other
stimuli) (43). We therefore tested whether feverfew
extracts mediate the release of TNF-a stimulated
by LPS. Pre-treatment of cells with feverfew extract
dramatically reduced LPS-mediated TNF-a release in
THP-1 cells in a dose dependent manner (Fig. 1).
LPS-mediated TNF-a release in THP-1 cells treated
with the 1  concentration (equivalent to 0.01% dry
weight) of feverfew was 46% of control cells untreated
with feverfew.
CCL2, (also known as monocyte chemoattractant
protein 1, MCP-1), appears in the list of feverfew-
responsive genes. We have observed that CCL2 is among
the genes whose expression is highly inhibited by the
feverfew extract (mRNA expression 40% of controls).
To determine whether inhibition of CCL2 expression is
reflected at the protein level, we studied LPS-mediated
CCL2 release by THP-1 cells. As expected, LPS-mediated
CCL2 release by THP-1 was strongly reduced in a
dose-dependent manner (Fig. 2). LPS-mediated CCL2
production was 27% of control in cells treated with the
1  concentration (0.01% dry weight) of feverfew extract.
At the 5 concentration of feverfew, no CCL2 production
was detected.
Discussion and Conclusions
Since monocytes/macrophages are key mediators of
inflammation and widely distributed in the body (26–28),
monocytic cell lines present an appropriate model
Table 2. Changes in expression of 10 representative feverfew-responsive
THP-1 genes: Comparison of microarray and RT–PCR data
Gene Name Microarray (fold change) RT-PCR (fold change)
AQP1 0.5 0.4
HMOX1 17.7 25.3
HOXA10 0.6 0.6
HSD17B7 2.1 1.9
HSPA1A 9.8 4.4
ID2 0.4 0.3
LDLR 2.4 2.6
PTAFR 0.7 0.5
RGS16 0.4 0.2
SPRY2 0.6 0.5
Each fold change is an average of four independent biological replicates
for microarray experiments, and of four independent biological
replicates for RT–PCR experiments.
Figure 1. Dose-dependent inhibition of LPS mediated production of
TNF-a by feverfew extracts. For each concentration treatment, the level
of TNF-a release is represented as a percentage of the control set at
100%. TNF-a release was significantly inhibited (46% of control) by
1X Feverfew (0.01%, w/v, dry weight).
**denotes P50.01 (Dunnett’s
Multiple Comparison Test), compared to control. The bar heights
represent the values of mean S.D. (standard deviation) from three
independent ELISA experiments. Control (Ctrl) cells received only
solvent.
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initiated a genomic approach (microarray analysis) to
search for molecular mechanisms by which feverfew
affects functions in human monocytic cells (THP-1).
It should be noted that among the 400 genes displaying
a differential response to feverfew in this study, only
about half (197 genes) contained annotated functions.
In spite of this limitation, it is clear that most of the
identified genes are primarily involved in cellular
metabolism: regulation of metabolism, nucleotide meta-
bolism, alcohol (i.e. alkyl compounds containing
a hydroxyl group) metabolism and lipid metabolism.
One possible interpretation is that at the level of gene
expression, feverfew in human monocytes may not
primarily or directly target known anti-inflammatory or
anti-infectious genes, but rather modulate pathways for
regulation of cellular metabolism.
However, the pre-ponderance of cellular metabolism
genes in the response pattern to feverfew by no means
negates a role for feverfew in anti-inflammatory or other
functions because cellular metabolism can impact other
pathways, including inflammation. This is apparent
in atherosclerosis, an inflammatory disease in which
lipid metabolism, e.g. oxidative modifications of LDL in
serum and lipid-laden macrophages, strongly impacts
the progression of atherosclerosis (44–46). Many of
the multiple feverfew functions (including some anti-
inflammatory effects) may derive from downstream
targets of diverse metabolic pathways. Another possibility
is that the action of feverfew may be focused on a few
key molecules/genes in anti-inflammatory pathways.
For example, in our microarray analyses, responsiveness
to feverfew was highest for HMOX-1 (Table 1). Previous
studies from several laboratories suggest that HMOX-1
mediates signaling pathways related to NF-kB (47), a key
component in inflammation.
Relevantly, our studies also suggest that feverfew
extracts are potent inhibitors of two pro-inflammatory
proteins, TNF-a and CCL2, in human THP-1 monocytes
(Figs. 1and 2). While previous studies have suggested that
parthenolide (a major constituent of feverfew) decreases
TNF-a release in rodent models (7,42), to our knowledge,
our study is the first to demonstrate the ability of
feverfew extracts to reduce LPS-mediated TNF-a and
CCL2 release in human monocytes. It should be noted
that the reduction by feverfew of LPS-induced TNF-a
release and LPS-induced CCL2 release probably occurs
by different mechanisms. Feverfew extracts exert an
inhibitory effect on LPS-induced TNF-a release
(Fig. 1), but do not appear to regulate the gene
expression of TNF-a. In contrast, feverfew inhibits
transcription of the CCL2 gene (Table 1) as well as
LPS-induced CCL2 release.
Monocytes/macrophages are major producers of diverse
cytokines and chemokines (48,49). It is likely that TNF-a
and CCL2 represent only a very small fraction of
cytokines and chemokines targeted by feverfew and that
the different effects of feverfew in the human body may
be due to its ability to target cytokines and chemokines
of diverse functions (including inflammatory or anti-
inflammatory effects).
Our cytokine and chemokine assays were based on the
stimulation of monocytes by LPS; a strong agonist
for toll-like receptor (TLR, especially TLR4) – mediated
signaling. Previous studies on other herbs have suggested
a role for TLRs in immune gene responses to herbal
medicine (50–52). It would be fruitful to investigate
whether TLRs play a role in mediating the effect of
feverfew in human cells.
In addition to CCL2, a gene related to chemokine
function, genes showing the greatest changes after
feverfew exposure include genes related to several
complex pathways. Heme regulation (HMOX1), chemo-
kine function (IL-8, and CMKOR1) and several heat
shock proteins (HSPA1A, DNAJB4, DNAJB1, HSPH1
and HSPA6) are highly elevated following feverfew
treatment. In contrast, expression of CCL2 and AQP1,
a gene involved in water homeostasis, is decreased
following feverfew treatment.
Of note, a common theme among the functions of the
AQP1, CCL2 and HMOX-1 is involvement in cell
migration. AQP1 (Aquaporin 1) not only functions as a
molecular water channel protein (53) but also localizes to
the leading edge of the cell membrane in many cells (54).
Figure 2. Dose-dependent inhibition of LPS mediated production of
CCL2 by feverfew extracts. For each concentration treatment, the level
of CCL2 release is represented as a percentage of the control set at
100%. CCL2 release was significantly inhibited (27% of control) by
1X Feverfew (0.01%, w/v, dry weight).
*denotes P50.05 significant
level and
**P50.01 significant level, compared to control (Dunnett’s
Multiple Comparison Test). The bar heights represent the values of
mean S.D. (standard deviation) from three independent ELISA
experiments. Control (Ctrl) cells received only solvent.
96 Treatment Using Medical Herb FeverfewCell migration of AQP1-deficient endothelial cells
is significantly slower than in WT cells (55).
HMOX-1 (heme oxygenase 1, also called HO-1) not
only is an essential enzyme in heme catabolism but also
plays a critical role in cell migration. HMOX-1 can
mediate cell migration by regulating the expression of
adhesion molecules. It has been shown that HMOX-1
induction down-modulates H2O2-mediated induction of
P-selectin and subsequently decreases leukocyte binding
in vivo (56). HMOX-1 induction also inhibits micro-
vascular leukocyte adhesion through the action of its
metabolites, bilirubin and CO (57–59). In addition,
increase of HMOX-1 expression inhibits leukocyte
infiltration in an in vivo mouse model of inflammatory
angiogenesis (60). Similarly, higher expression of
HMOX-1 correlates with decreased migration of peri-
toneal macrophages and bone marrow cells harvested
from morphine-receiving mice (61).
The CCL2 protein is a CC chemokine that mediates
monocyte recruitment and entry into vessel walls at sites
of atherosclerosis (46). CCL2 is produced by multiple
cell types, including macrophages, endothelial cells and
smooth muscle cells, all of which are important players in
atherogenesis (60). In addition, CCL2 may play a role in
multiple sclerosis (MS) (61) and in cancer pathobiology
(62). Interestingly, the reduction of CCL2 expression
might well be a direct result of HMOX-1. In human
U937 monocytes, increase of HMOX-1 by hemin is
correlated with the suppression of CCL2 mRNA expres-
sion (62). Similarly, in other cell types over-expression
of HMOX-1 is usually accompanied by reduction of
CCL2 (63,64). Together these data suggest that these
three genes represent a possible pathway by which
feverfew acts on cell migration.
In summary, this study utilized a human monocytic cell
line as a model system to identify gene responses to
feverfew. We are aware that the THP-1 cell line was
established from a single individual and that there is
genetic variability of the gene responses to feverfew
extracts in human populations. We are therefore prepar-
ing to confirm the effects of feverfew on select genes
in vivo. It is important to establish feverfew concentra-
tions in blood samples of patients undertaking feverfew
treatments and to determine concentrations of feverfew
effective for modulating gene responses in vivo.
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